AP-III-a4: An integrated approach identifies new oncotargets in melanoma

Ertugliflozin : Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus